Novartis

Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. The Company's businesses are divided into three operating divisions: Pharmaceuticals, Alcon (eye care) and Sandoz (generics). Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan) and imatinib mesylate (Gleevec/Glivec). Additional agents include ciclosporin (Neoral/Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil) and others. The Company is one of the largest pharmaceutical companies by both market cap and sales.

Company Growth (employees)
Type
Public
HQ
Basel, CH
Founded
1996
Size (employees)
121,000 (est)+2%
Novartis was founded in 1996 and is headquartered in Basel, CH

Key People/Management at Novartis

Joseph Jimenez

Joseph Jimenez

Chief Executive Officer
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Paul van Arkel

Paul van Arkel

Head of Corporate Strategy and Healthcare Systems
Peter Elam

Peter Elam

Head of Internal Audit
Erwin Vanhaecke

Erwin Vanhaecke

Head Novartis Group Quality
Michael Willi

Michael Willi

Group Head of Communications
Felix Ehrat

Felix Ehrat

Group General Counsel
Richard Francis

Richard Francis

CEO, Sandoz
Andre Wyss

Andre Wyss

President, Novartis Operations Country President for Switzerland
Juergen Brokatzky-Geiger

Juergen Brokatzky-Geiger

Global Head, Corporate Responsibility for Novartis
Michael Ball

Michael Ball

CEO, Alcon
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Bruno Strigini

Bruno Strigini

CEO, Novartis Oncology
Steven Baert

Steven Baert

Head of Human Resources

Novartis Office Locations

Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH (HQ)
Forum 1, Novartis Campus
Tokyo, JP
Toranomon Hills, Mori Tower, 1-23-1, Toranomon, Minato-ku
Beijing, CN
14th floor, China World Tower 2, No.1 Jian Guo Men Wai Avenue, Chao Yang District
Wehr, DE
Oeflingerstrasse 44
New York, US
230 Park Avenue, 21st Floor
East Hanover, US
1 Health Plazam, Bldg. 101

Novartis Financials and Metrics

Novartis Financials

Novartis's revenue was reported to be $48.5 b in FY, 2016 which is a 2% decrease from the previous period.
USD

Revenue (FY, 2016)

48.5 b

Revenue growth (FY, 2015 - FY, 2016), %

(2%)

Gross profit (FY, 2016)

31 b

Gross profit margin (FY, 2016), %

64%

Net income (FY, 2016)

6.7 b

Market capitalization (31-Jan-2017)

175.5 b

Closing share price (31-Jan-2017)

72.3
Novartis's current market capitalization is $175.5 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

53.6 b49.4 b48.5 b

Revenue growth, %

(8%)(2%)

Cost of goods sold

17.3 b17.4 b17.5 b

Gross profit

36.3 b32 b31 b
USDFY, 2015FY, 2016

Cash From Operating Activities

12.1 b11.5 b
USDY, 2016

Revenue/Employee

407.7 k
Show all financial metrics

Novartis Operating Metrics

Y, 2015Y, 2016

Patients Reached

972 m965 m

Projects Entering Development Pipeline

85

Major Submissions (US, EU, JP)

1424

Major Approvals (US, EU, JP)

2016
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Advanced Accelerator ApplicationsOctober 30, 2017$3.9 b

Novartis Market Value History

Novartis Revenue Breakdown

Novartis Median Salaries

Source: 453 public H-1B filings from Novartis

Novartis's Web-traffic and Trends

Novartis Online and Social Media Presence

Novartis News and Updates

Self-administered Drugs Global Market 2017: Key Players – Abbott Laboratories, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Gilead Sciences

Self-administered Drugs -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2022 Posted via Industry Today. Follow us on Twitter @IndustryToday

Novartis chases new canakinumab niche after overall data failed to excite

Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers," the company's CEO-to-be, Vas Narasimhan, said on a Monday conference call. Now, Novartis is back with subgroup data for the proposed cardiovascular drug it thinks are more p…

Novartis looks past psoriasis for even bigger Cosentyx growth frontier

Novartis’ Cosentyx currently leads a crop of next-gen immunology products from a who’s who of Big Pharma. And the Swiss drugmaker intends to keep it that way.

Tonsil Cancer Market by Surgery, Radiation Therapy, etc. Treatment, Analysis and Forecast by 2023

Tonsil cancer market information: by type (squamous cell carcinoma, salivary gland cancer, and others), diagnosis, by treatment, by end user- global forecast till 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

Osteoarthritis Market 2017 – Hypothesis Investigation Report 2022

The examination report overall Osteoarthritis Market covers the market investigation for the areas - North America, Europe, Asia Pacific/Southeast Asia and Row and nation investigation of China, Japan, and India concentrating on top makers in world market and the piece of the overall industry they h…

Drug giant Novartis is going after a $5 billion eye-drug market

Novartis on Friday showed that its drug, brolucizumab, worked as well as an existing drug that's used to treat age-related macular degeneration.  It's a condition that affects more than 2 million people in the US.  The hope is to get the drug approved to take on a roughly $5 billion market.  Nova…
Show more

Novartis Company Life and Culture

You may also be interested in